Summary & Overview
Other Digestive System Diagnoses without CC/MCC: Inpatient Reimbursement Overview
DRG 395 groups inpatient stays for other digestive system diagnoses without Complication or Comorbidity or Major Complication or Comorbidity and reflects lower clinical severity. It matters for inpatient reimbursement because payment is calibrated to the absence of higher-severity diagnoses, influencing hospital revenue for routine digestive admissions.
DRG 395 Overview
DRG 395 covers inpatient admissions for other digestive system diagnoses without Complication or Comorbidity or Major Complication or Comorbidity. Typical cases include non-complicated gastrointestinal conditions, minor biliary disorders, and diagnostic evaluations that do not meet higher severity criteria. This grouping matters for Medicare payment because it assigns a lower relative weight and payment level compared with cases that include Complication or Comorbidity or Major Complication or Comorbidity, affecting hospital reimbursement for routine digestive admissions.
Clinical Trials
- Acute procedural and perioperative management studies: trials evaluating optimal approaches to endoscopic, surgical, or interventional procedures for non-complex digestive diagnoses (for example, endoscopic hemostasis strategies for bleeding peptic ulcers, procedural timing for obstructive biliary conditions without major comorbidity, or minimally invasive versus conventional techniques for benign small-bowel resections). These studies enroll hospitalized adults presenting with acute but non-MCC-bearing digestive conditions, focusing on procedural success, short-term complications, and length of stay. Findings directly inform inpatient resource utilization, complication rates, and procedural choice decisions that affect reimbursement and case-mix assignment for DRG 395 patients.
- Comparative effectiveness and care pathway trials for medical management: randomized or pragmatic studies comparing non-surgical medical strategies such as antibiotic stewardship approaches, acid-suppression regimens, or standardized protocols for opioid-sparing pain control and bowel rest in patients with acute, non-complicated digestive conditions (for example, mild pancreatitis or uncomplicated diverticulitis managed without major complications). These trials target adult inpatients and observation stays to determine which medical pathways reduce readmissions, complications, and length of stay. Results are relevant to clinicians and payers because they can identify cost-effective care bundles and protocols that reduce utilization while maintaining clinical quality for cases categorized in DRG 395.
- Post-discharge outcomes, transitions of care, and quality-of-life studies: cohort and interventional studies assessing discharge planning, outpatient follow-up timing, nutrition support, and patient-reported outcomes for patients hospitalized with non-complex digestive disorders (for example, monitoring recurrence, functional recovery, and outpatient resource use after hospitalization for non-complicated GI bleeding or inflammatory colitis). These studies include efforts to reduce preventable readmissions and emergency visits through enhanced discharge interventions and care coordination. The evidence guides hospitals and payers on effective transitional care strategies that can lower downstream costs and improve value for the DRG 395 population.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.